In the last years, collaborative studies have joined to link the degree of genetic heterogeneity of acute myeloid leukemia (AML) to clinical outcome, 1,2 allowing risk stratification before therapy and guiding post-induction treatment of children with AML. So far, still half of these patients, whose disease is usually characterized by a grim prognosis, lack a known biomarker offering opportunities of targeted treatment. This relevant limitation prompted to pursue the search of new prognostic biomarkers to address also these forms of still uncharacterized AML. We chose to investigate NUP98 for its attitude to rearrange with different gene partners and produce oncogenic fusion transcripts often found to be associated with a wide range of hematological disorders, including leukemia. 3 NUP98 rearrangements have been mainly mechanistically associated with oncogenic activation of HOX-AB cluster genes, a process largely documented for MLL-rearranged AML, [4] [5] [6] in cooperation with other recurrent genetic defects, in particular FLT3-ITD. 7 The frequency and prognostic relevance of NUP98 fusions in a single-center cohort of childhood AML has been recently reported, 8 but neither the frequency nor the role of diverse NUP98 partners have been investigated. Here, we report an exhaustive molecular screening of 12 NUP98 rearrangements in the Italian pediatric patients with de novo AML enrolled in the AIEOP-AML 2002/01 trial. 9 By RT-PCR, we characterized, at diagnosis, 494 patients harboring CBF rearrangements (RUNX1-RUNX1T1 and CBFB-MYH11, N = 99), MLL-translocations (N = 86), FLT3-ITD (N = 54) and rarer mutations/translocations (N = 83), 7, 10 whereas in 172 patients no mutations were detected (35%). Among these 172 patients without known mutations and 36 patients with isolated FLT3-ITD 11 mutation we searched for NUP98 rearrangements with NSD1, HOXC11, PHF23, HOXA9, JARID1A, HOXD13, LEDGF, DDX10, HHEX, ADD3, NSD3 and LOC348801, finding 16 (9.3%) with 6 different NUP98 fusions (16/172 = 9.3%) and 9 with t(5;11)NUP98-NSD1, respectively (9/36 = 25%, Supplementary Table 1S and 2S). In the 16 patients with NUP98 fusions, no CEBPA mutations were found, while 2 patients had K-RAS mutation, one of which concomitant with NPM1 mutation. Survival analyses revealed that the NUP98-t (N = 16) had a significant worse event-free survival (EFS, 25%) compared with the rest of AML (49.7%) patients without known mutations (N = 156, Neg in Figure 1a , P o0.01), and significantly higher incidence of relapse (Figure 1a , 66.3 vs 33.6% P-value o 0.01, Supplementary Table 1S ). Reduced EFS and increased CIR were found also in the 9 NUP98-t patients with a concomitant FLT3-ITD mutation similar to isolated t(5;11) (Figure 1a) . Collectively, in the whole AIEOP-AML trial cohort, we identified 25 NUP98-t patients (5%) characterized by a severe prognosis (Supplementary Figures  1SA-C) . We then characterized NUP98-rearranged patients (n = 19) by using gene expression profiling (GEP) and compared them to 66 cases of AML with various genetic abnormalities (see Supplementary Methods, GSE75461). Supervised clustering showed that most of the NUP98-AML cases grouped independently of the rest of AML cases (Figure 1b Table 3SAB ). In particular, the coding transcript clusters revealed 76 differentially expressed mRNAs (P-value o 0.05), where most of the upregulated genes were confirmed to belong to the HOX family, in particular the HOX-B cluster (see non-coding clustering analysis at Supplementary Figure 2SB ), and the most downregulated were all genes involved in mitosis and nuclear division (CPNE8, CPNE3, CCNA1, FAS, DEFA423 being also validated by RQ-PCR Supplementary Figure 2SC) . By gene ontology, we confirmed their involvement in the regulation of mitosis and chromatin modification (Supplementary Figure 2SD , Supplementary Table 4S), this finding supporting the role of NUP98 fusions in increasing genome instability. 12 We further investigated this finding in ex vivo blasts obtained at diagnosis from t(5;11)NUP98-NSD1-rearranged patients and implanted in NSG mice (Supplementary Methods). We revealed spindle assembly checkpoint (SAC) defects in total cell extracts from NUP98-t cells arrested in M-phase after treatment with the microtubule-depolymerizing drug nocodazole (Noco), but no defects were found in BM cells from healthy donors (HBM) used as control. MAD2 and BUB1 protein levels decreased starting from 8 h post-Noco treatment, whereas Cyclin B levels increased, indicating that NUP98-t cells had an early and uncontrolled entrance in mitosis (Supplementary Figure 3SA) . Then, we blocked DNA replication using aphidicolin (APH) and found an increased number of mitotic chromosomal breaks 24 h post treatment in NUP98-t cells compared with HBM cells (Supplementary Figure 3SB ). This latter result was confirmed by protein analysis, which showed PP2A subunit β in the cytoplasm and phosphorylated H2AX (γH2AX) in the nucleus for the recruitment of enzymes to repair DNA in NUP98-t cells. This phenomenon was absent in HBM cells, where γH2AX was detected in the cytoplasm and PARP was found to be cleaved, suggesting that apoptosis occurred probably due to incapability of healthy cells to repair DNA and survive at the same APH dose (Figure 1c) .
We then moved to NUP98 partner gene characterization, finding evidence that NUP98-t patients significantly differentially expressed 101 transcript clusters independently of what was found in the rest of AML cases (60 coding and 41 non-coding RNAs, Supplementary Table 4S , Kruskal-Wallis test, P-value o 0.01; Figure 2a , Supplementary Table 5S) . We focused our attention on HOX-AB cluster genes expression and found that, having NSD1 as partner gene, conferred the lowest HOX-AB expression among the six different NUP98-translocations (Figure 2a , Supplementary Figure 4SA , P-value o 0.05). Different GEP sustained a different survival depending on partner gene, with NSD1 mediating the worst prognosis (NSD1 N = 12; PHF23+JARID1A N = 7, Supplementary Figure 4SBC , P o0.05). In order to identify peculiarities among the different NUP98 fusions, we performed enrichment analysis for several selected molecular signatures (Supplementary Methods). We found that all were enriched in chromosome instability and HOX/MLL signatures, with the exception of that involving PHF23, which showed correlation with methylation test *P-value o 0.05). Gene set enrichment analysis further confirmed that NUP98-t transcriptional profiles were enriched in genes dependent on CREB activity, that is, cAMP and GSK3 signaling (Supplementary Figure 5SA) . CREB is a proto-oncogene in pediatric AML, and its overexpression has been largely demonstrated to induce aberrant cell proliferation and cell cycle regulation of hematopoietic cells. 14 We investigated in vitro if CREB could be involved in the transcriptional control of NUP98 and NUP98 fusions strengthened by the presence of CREB consensus regions (the cAMP response elements, CREs) at the site of the NUP98 promoter (from 1,300 bases upstream of the NUP98 transcription start site). By chromatin immunoprecipitation, we confirmed that CREB worked as transcription factor at the NUP98 gene promoter in myeloid leukemia cells (Supplementary Figure 5SB) . Furthermore, we co-expressed exogenous CREB (pEGFP-flag-CREB) with a reporter gene (LUC) under the control of the wild-type-NUP98 promoter, revealing that CREB-mediated LUC overactivation. On the contrary, when we induced mutagenesis at CREs, LUC activity significantly decreased. Moreover, by CREB gene silencing, LUC activity was found to be reduced, as well as NUP98 protein levels (Figure 2c, Supplementary Figure 5SC) , confirming the hypothesis of CREB controlling NUP98 gene expression. The same experiment of CREB genetic silencing was performed in ex vivo cells from three AML patients at diagnosis harboring t(5;11)NUP98-NSD1, revealing a reduced NUP98-NSD1 chimera at both RNA and protein levels (Supplementary Figure 6SAB , P-valueo0.01). These results for the first time show that inhibiting CREB and its binding to the NUP98 promoter may constitute a reliable strategy 15 to destabilize NUP98-chimera expression.
In summary, we screened 12 NUP98 rearrangements in a large pediatric cohort of Italian children with AML and found that 6 of them identified a new subgroup of recurrent somatic translocations with a total frequency of 5%. NUP98-rearranged patients had an incidence of relapse higher than that of the general high-risk AML, resulting into poorer EFS. We found that NUP98-leukemia arises as a sequence of biologically distinct phenomena where each partner gene plays a unique role and that NUP98 fusions identify a novel AML subgroup functionally independent from the rest of AML. To the best of our knowledge, this is the first study documenting in primary NUP98-NSD1-rearranged leukemia cells an altered spindle assembly checkpoint and an aberrant response to DNA damage. These evidences confirmed that NUP98 cells suffer from enhanced genomic instability, which may contribute to a more pronounced transcriptional variability and to the Figure 1 . Characterization of NUP98-t pediatric AML. (a) EFS probability and CIR in 9 and 16 children with NUP98-t with and without FLT3-ITD, respectively, as compared to the molecularly negative patients enrolled in the Italian AML cohort (P-valueo 0.05). N, number of cases; EFS, event-free survival; CIR, cumulative incidence of relapse. (b) Supervised hierarchical clustering analysis (using 76 differentially expressed coding RNAs (P-valueo 0.01). (c) Western blot of lysates after APH treatment. The expression of PP2A-B55α in the cytoplasm and γH2Ax in the nucleus of NUP98-NSD1 primary cells revealed cell integrity and chromosome instability, whereas cytoplasmic γH2Ax and the increased PARP cleaved (cl) in the HBM revealed that apoptosis occurred. β-ACTIN and PARP1 total (total) represent the loading controls of cytoplasmic and nuclear extracts, respectively. acquisition of cooperating mutations, which can concur to the severe prognosis. Collaborative studies in larger cohorts are warranted to yield additional insights into the clinical and biological role played by NUP98-fusion transcripts. Notably, we documented that CREB is the transcriptional factor controlling NUP98 expression; thus, its targeting could be further investigated as a novel potential strategy for the treatment of this subtype of AML.
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VB, EM, CT, VS, DDG, MT, performed in vitro experiments; MZ performed GEP analysis; AL, ADM, CM, VZ performed and interpreted cytogenetic analysis; SM performed xenotransplantation in NSG mice; RR, EM, RM performed the statistical analysis; FL, GB, MP designed the research, analyzed and interpreted data, wrote the manuscript. T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a heterogeneous and aggressive haematological malignancy. This cancer arises from the malignant proliferation of T-cell progenitor cells, arrested at different stages of development, and it accounts for 10-15% of pediatric acute lymphoblastic leukaemias (ALLs) and 30% of adult BCR-ABL negative ALLs. In the past years, the development of multi-agent chemotherapy protocols has significantly improved the clinical outcome of this disease, inducing remission in 95% of pediatric and 80% of adult T-ALL patients. Nevertheless, the overall survival rate in patients resistant to chemotherapy or undergoing relapse is o 25%.
1 Since T-ALL chemo-resistance is linked to the activation of pathways that promote and sustain the self-renewal of leukaemia-initiating cells (LICs), 2, 3 it is imperative to develop novel therapies to eradicate these cells. To accomplish this objective, it is necessary to perform pre-clinical functional studies with human primary T-ALL samples, a challenging task given that tools enabling efficient genetic manipulation of primary T-ALL cells are still lacking. In this study, we demonstrated that lentiviral vectors pseudotyped with a baboon retroviral envelope are excellent tools to genetically modify T-ALL leukaemia-initiating cells without interfering with their growth in xenograft models. In order to develop novel strategies to genetically manipulate T-ALL leukaemia-initiating cells (LIC), we first examined whether primary T-ALL cells express the receptors for different lentiviral vector pseudotyping glycoproteins, such as the vesicular-stomatitis-virus G protein (VSVG), 4 the measles virus hemagglutinin (H) and fusion (F) glycoproteins, 5 and the baboon retroviral envelope glycoprotein (BaEV). 6 As shown in Figure 1a and Supplementary  Figures 1A and B , the VSVG receptor LDL-R (low density lipoprotein receptor) 7 and the measles virus receptor CD150 8 were only weakly expressed on the leukemic blasts and their expression did not increase, even when the cells were stimulated in vitro with cytokines, insulin and the DL1 Notch1 ligand. In contrast, CD46, the second measles virus receptor, 9 was already highly expressed on unstimulated primary T-ALL cells and its levels further increased following cytokine stimulation (Figure 1a and Supplementary Figures 1A and B) . Similar results were observed when analysing CD34+ blasts, putatively enriched in leukaemiainitiating cells 10, 11 (Supplementary Figure 1C) . Next, we analysed ASCT1 and ASCT2, the two neutral aminoacid transporters that are exploited by the baboon retrovirus to enter host cells. 12, 13 Given the Accepted article preview online 6 December 2016; advance online publication, 13 January 2017
